Targeting RET-rearranged lung cancers with multikinase inhibitors

Oncoscience. 2017 Apr 14;4(3-4):23-24. doi: 10.18632/oncoscience.345. eCollection 2017 Mar.

Authors

Joshua K Sabari¹, Evan D Siau¹, Alexander Drilon¹

Affiliation

¹ Developmetal Therapeutics, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, 10065, USA.

No abstract available

Keywords: BLU-667; LOXO-292; RET; RXDX-105; cabozantinib; non-small cell lung cancer; tyrosine kinase inhibitor; vandetanib.

Publication types

Editorial